Cancer-testis genes as candidates for immunotherapy in breast cancer

Immunotherapy

Volumn 6, Issue 2, 2014, Pages 165-179

  Ghafouri Fard, Soudeh ^a   Shamsi, Roshanak ^a   Seifi Alan, Mahnaz ^a   Javaheri, Mona ^a   Tabarestani, Sanaz ^a  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

Author keywords

breast cancer; cancer stem cell; cancer testis gene; immunotherapy; tumor vaccine

Indexed keywords

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MALE; TESTICULAR NEOPLASMS; TESTIS;

EID: 84893819688     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.165     Document Type: Review

References (113)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
2. Dreyer G, Vandorpe T, Smeets A et al. Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast 22(5), 761-766 (2013).
3. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch. Iran Med. 12(4), 395-404 (2009).
4. Bart J, Groen HJ, Van Der Graaf WT et al. An oncological view on the blood-testis barrier. Lancet Oncol. 3(6), 357-363 (2002). (Pubitemid 34661985)
5. Ghafouri-Fard S, Modarressi MH. Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy 4(1), 59-75 (2012).
6. Dianatpour M, Mehdipour P, Nayernia K et al. Expression of testis specific genes TSGA10, TEX101 and ODF3 in breast cancer. Iran Red Crescent Med. J. 14(11), 722-726 (2012).
7. Ghafouri-Fard S. Immunotherapy in nonmelanoma skin cancer. Immunotherapy 4(5), 499-510 (2012).
8. Ghafouri-Fard S, Modarressi MH. Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient. Genet. Mol. Res. 11(4), 3642-3648 (2012).
9. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
10. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
11. Tabarestani S, Ghafouri-Fard S. Cancer stem cells and response to therapy. Asian Pac. J. Cancer Prev. 13(12), 5951-5958 (2012).
12. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther. 4(1), 50-60 (2009).
13. Pece S, Tosoni D, Confalonieri S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1), 62-73 (2010).
14. Ghafouri-Fard S, Abdollahi DZ, Omrani M, Azizi F. shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac. J. Cancer Prev. 13(11), 5865-5869 (2012).
15. Ghafouri-Fard S, Modarressi MH, Yazarloo F. Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity. Ann. Saudi Med. 32(3), 256-261 (2012).
16. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25(3), 707-711 (2007). (Pubitemid 46354230)
17. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 65(6), 2207-2215 (2005). (Pubitemid 40490129)
18. Yamada R, Takahashi A, Torigoe T et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 81(6), 428-434 (2013).
19. Balafoutas D, Zur Hausen A, Mayer S et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 13, 271 (2013).
20. Ono T, Kurashige T, Harada N et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc. Natl Acad. Sci. USA 98(6), 3282-3287 (2001). (Pubitemid 32220837)
21. Cen YH, Guo WW, Luo B et al. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol. Int. 36(10), 917-922 (2012).
22. Chiriva-Internati M, Yu Y, Mirandola L et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 72(1), 12-23 (2012).
23. Saini S, Jagadish N, Gupta A, Bhatnagar A, Suri A. A novel cancer testis antigen, A-kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer. PLoS ONE 8(2), e57095 (2013).
24. Ciro M, Prosperini E, Quarto M et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 69(21), 8491-8498 (2009).
25. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERa, is required for coregulator occupancy and chromatin modification. Proc. Natl Acad. Sci. USA 104(46), 18067-18072 (2007). (Pubitemid 350210821)
26. Fujie T, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann. Oncol. 8(4), 369-372 (1997). (Pubitemid 27230978)
27. Boel P, Wildmann C, Sensi ML et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2(2), 167-175 (1995).
28. Parmigiani RB, Bettoni F, Vibranovski MD et al. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc. Natl Acad. Sci. USA 103(48), 18066-18071 (2006). (Pubitemid 44871613)
29. Chen YT, Scanlan MJ, Venditti CA et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc. Natl Acad. Sci. USA 102(22), 7940-7945 (2005). (Pubitemid 40781042)
30. Koop A, Sellami N, Adam-Klages S et al. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun. Signal. 11(1), 41 (2013).
31. Chen YT, Chadburn A, Lee P et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc. Natl Acad. Sci. USA 107(7), 3093-3098 (2010).
32. Chen YT, Hsu M, Lee P et al. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int. J. Cancer 124(12), 2893-2898 (2009).
33. Theurillat JP, Ingold F, Frei C et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int. J. Cancer 120(11), 2411-2417 (2007). (Pubitemid 46642128)
34. Ademuyiwa FO, Bshara W, Attwood K et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 7(6), e38783 (2012).
35. Curigliano G, Viale G, Ghioni M et al. Cancer-testis antigen expression in triple-negative breast cancer. Ann. Oncol. 22(1), 98-103 (2011).
36. Grigoriadis A, Caballero OL, Hoek KS et al. CT-X antigen expression in human breast cancer. Proc. Natl Acad. Sci. USA 106(32), 13493-13498 (2009).
37. Taylor M, Bolton LM, Johnson P, Elliott T, Murray N. Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res. 9(4), R46 (2007).
38. Hamai A, Duperrier-Amouriaux K, Pignon P et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE 6(6), e21129 (2011).
39. Adams S, Greeder L, Reich E et al. Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol. Immunother. 60(7), 999-1007 (2011).
40. Matkovic B, Juretic A, Spagnoli GC et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat. Med. J. 52(2), 171-177 (2011).
41. Usener D, Schadendorf D, Koch J, Dubel S, Eichmuller S. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J. Invest. Dermatol. 121(1), 198-206 (2003). (Pubitemid 36900473)
42. Loukinov DI, Pugacheva E, Vatolin S et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl Acad. Sci. USA 99(10), 6806-6811 (2002). (Pubitemid 34526213)
43. D'arcy V, Pore N, Docquier F et al. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br. J. Cancer 98(3), 571-579 (2008). (Pubitemid 351214517)
44. Kohn MJ, Kaneko KJ, Depamphilis ML. DkkL1 (Soggy), a Dickkopf family member, localizes to the acrosome during mammalian spermatogenesis. Mol. Reprod. Dev. 71(4), 516-522 (2005). (Pubitemid 40923519)
45. Koslowski M, Tureci O, Bell C et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res. 62(22), 6750-6755 (2002). (Pubitemid 35364147)
46. Bettoni F, Filho FC, Grosso DM et al. Identification of FAM46D as a novel cancer/testis antigen using EST data and serological analysis. Genomics 94(3), 153-160 (2009).
47. Chapman KB, Prendes MJ, Kidd JL, Sternberg H, West MD, Wagner J. Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors. Biomark. Med. 7(4), 601-611 (2013).
48. Gjerstorff MF, Rosner HI, Pedersen CB et al. GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL). PLoS ONE 7(9), e45819 (2012).
49. Caballero OL, Cohen T, Gurung S et al. Effects of CT-Xp gene knock down in melanoma cell lines. Oncotarget 4(4), 531-541 (2013).
50. Van Den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182(3), 689-698 (1995).
51. Chen YT, Ross DS, Chiu R et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS ONE 6(3), e17876 (2011).
52. Zhou X, Yang F, Zhang T et al. Heterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma. Jpn J. Clin. Oncol. 43(3), 243-250 (2013).
53. Chen YT, Venditti CA, Theiler G et al. Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. Cancer Immun. 5, 9 (2005).
54. Tureci O, Sahin U, Koslowski M et al. A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene 21(24), 3879-3888 (2002). (Pubitemid 34620856)
55. Mischo A, Kubuschok B, Ertan K et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int. J. Cancer 118(3), 696-703 (2006). (Pubitemid 43076020)
56. Lurquin C, De Smet C, Brasseur F et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics 46(3), 397-408 (1997). (Pubitemid 28063288)
57. Park JW, Kwon TK, Kim IH et al. A new strategy for the diagnosis of MAGE-expressing cancers. J. Immunol. Methods 266(1-2), 79-86 (2002). (Pubitemid 34804674)
58. Wascher RA, Bostick PJ, Huynh KT et al. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br. J. Cancer 85(9), 1340-1346 (2001). (Pubitemid 33081930)
59. Badovinac Crnjevic T, Spagnoli G, Juretic A, Jakic-Razumovic J, Podolski P, Saric N. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Med. Oncol. 29(3), 1586-1591 (2012).
60. Karn T, Pusztai L, Ruckhaberle E et al. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur. J. Cancer 48(1), 12-23 (2012).
61. Hamai A, Memeo L, Colarossi C et al. Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers. Annu. Oncol. 22(4), 986-987 (2011).
62. Lian Y, Sang M, Ding C et al. Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study. J. Cancer Res. Clin. Oncol. 138(3), 519-527 (2012).
63. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol. Cell. Biol. 32(20), 4131-4140 (2012).
64. Ait-Tahar K, Liggins AP, Collins GP et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br. J. Haematol. 146(4), 396-407 (2009).
65. Ghafouri-Fard S, Abbasi A, Moslehi H et al. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br. J. Dermatol. 162(4), 772-779 (2010).
66. Lee JH, Jung C, Javadian-Elyaderani P et al. Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res. 70(11), 4569-4579 (2010).
67. Liu JJ, Shen R, Chen L et al. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int. J. Clin. Exp. Pathol. 3(4), 328-337 (2010).
68. Silva WA Jr, Gnjatic S, Ritter E et al. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun. 7, 18 (2007).
69. Massabbal E, Parveen S, Weisoly DL, Nelson DM, Smith SD, Fant M. PLAC1 expression increases during trophoblast differentiation: evidence for regulatory interactions with the fibroblast growth factor-7 (FGF-7) axis. Mol. Reprod. Dev. 71(3), 299-304 (2005). (Pubitemid 40770383)
70. Dong XY, Peng JR, Ye YJ et al. Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int. J. Cancer 122(9), 2038-2043 (2008).
71. Old LJ. Cancer is a somatic cell pregnancy. Cancer Immun. 7, 19 (2007).
72. Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C, Tureci O. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 67(19), 9528-9534 (2007). (Pubitemid 47535943)
73. Liu W, Zhai M, Wu Z et al. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer. Amino Acids 42(6), 2257-2265 (2012).
74. Bera TK, Saint Fleur A, Lee Y et al. POTE paralogs are induced and differentially expressed in many cancers. Cancer Res. 66(1), 52-56 (2006). (Pubitemid 43166008)
75. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br. J. Cancer 99(3), 398-403 (2008).
76. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 60(14), 3848-3855 (2000). (Pubitemid 32204577)
77. Sapiro R, Kostetskii I, Olds-Clarke P, Gerton GL, Radice GL, Strauss IJ. Male infertility, impaired sperm motility, and hydrocephalus in mice deficient in sperm-associated antigen 6. Mol. Cell. Biol. 22(17), 6298-6305 (2002). (Pubitemid 34857847)
78. Silina K, Zayakin P, Kalnina Z et al. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J. Immunother. 34(1), 28-44 (2011).
79. Tureci O, Chen YT, Sahin U et al. Expression of SSX genes in human tumors. Int. J. Cancer 77(1), 19-23 (1998). (Pubitemid 28308546)
80. Sahin U, Tureci O, Chen YT et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer 78(3), 387-389 (1998). (Pubitemid 28445380)
81. Mashino K, Sadanaga N, Tanaka F et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer 85(5), 713-720 (2001). (Pubitemid 32929470)
82. Modarressi MH, Behnam B, Cheng M, Taylor KE, Wolfe J, Van Der Hoorn FA. Tsga10 encodes a 65-kilodalton protein that is processed to the 27-kilodalton fibrous sheath protein. Biol. Reprod. 70(3), 608-615 (2004). (Pubitemid 38233697)
83. Modarressi MH, Cameron J, Taylor KE, Wolfe J. Identification and characterisation of a novel gene, TSGA10, expressed in testis. Gene 262(1-2), 249-255 (2001). (Pubitemid 32155356)
84. Hagele S, Behnam B, Borter E et al. TSGA10 prevents nuclear localization of the hypoxia-inducible factor (HIF)-1alpha. FEBS Lett. 580(15), 3731-3738 (2006). (Pubitemid 43902807)
85. Behnam B, Chahlavi A, Pattisapu J, Wolfe J. TSGA10 is specifically expressed in astrocyte and over-expressed in brain tumors. Avicenna J. Med. Biotechnol. 1(3), 161-166 (2009).
86. Mobasheri MB, Modarressi MH, Shabani M et al. Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). Leuk. Res. 30(7), 883-889 (2006). (Pubitemid 43816697)
87. Mobasheri MB, Jahanzad I, Mohagheghi MA, Aarabi M, Farzan S, Modarressi MH. Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect. Prev. 31(4), 296-302 (2007). (Pubitemid 47562628)
88. Yuan L, Shan J, De Risi D et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res. 59(13), 3215-3221 (1999). (Pubitemid 29316025)
89. Finkelstein SE. From bench to bedside: bringing immunotherapy into the clinic. Cancer Control 20(1), 4-5 (2013).
90. Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control 20(1), 17-21 (2013).
91. Barok M, Isola J, Palyi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6(7), 2065-2072 (2007). (Pubitemid 47052497)
92. Soliman H. Developing an effective breast cancer vaccine. Cancer Control 17(3), 183-190 (2010).
93. Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy 4(9), 907-917 (2012).
94. Sabel MS, Nehs MA. Immunologic approaches to breast cancer treatment. Surg. Oncol. Clin. N. Am. 14(1), 1-31 (2005). (Pubitemid 39487185)
95. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast 18(Suppl. 3), S51-S54 (2009).
96. Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs 23(5), 277-287 (2009).
97. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 110(8), 1677-1686 (2007). (Pubitemid 47557292)
98. Emens LA, Asquith JM, Leatherman JM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 27(35), 5911-5918 (2009).
99. Dols A, Meijer SL, Smith JW 2nd, Fox BA, Urba WJ. Allogeneic breast cancer cell vaccines. Clin. Breast Cancer 3(Suppl. 4), S173-S180 (2003).
100. De Gruijl TD, Van Den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57(10), 1569-1577 (2008).
101. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen lapuleucel-T: results of a Phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J. Clin. Oncol. 25(24), 3680-3687 (2007). (Pubitemid 47372607)
102. Garnett CT, Greiner JW, Tsang KY et al. TRICOM vector based cancer vaccines. Curr. Pharm. Des. 12(3), 351-361 (2006).
103. Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14(3), 797-803 (2008). (Pubitemid 351231162)
104. Holmes JP, Benavides LC, Gates JD et al. Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426-3433 (2008).
105. Carmichael MG, Benavides LC, Holmes JP et al. Results of the first Phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 116(2), 292-301 (2010).
106. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in Phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6, 24 (2008).
107. Miles D, Roche H, Martin M et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8), 1092-1100 (2011).
108. Dols A, Smith JW 2nd, Meijer SL et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum. Gene Ther. 14(11), 1117-1123 (2003). (Pubitemid 36851402)
109. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007). (Pubitemid 46039831)
110. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
111. Schmidt M, Ruttinger D, Sebastian M et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann. Oncol. 23(9), 2306-2313 (2012).
112. Ibrahim NK, Yariz KO, Bondarenko I et al. Randomized Phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin. Cancer Res. 17(21), 6822-6830 (2011).
113. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. 86(3), 231-245 (2006). (Pubitemid 43276955)